Pfizer seeks partner for osteoporosis drug Fablyn as it secures first approval
This article was originally published in Scrip
Executive Summary
Pfizer has decided to seek a global out-license partner for its osteoporosis drug Fablyn (lasofoxifene), the company told Scrip. The launch of the drug in the EU, its first worldwide market, will occur once Pfizer secures a partner, it said.